Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · see citing works

BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER

Gottesman, M. M., & PASTAN, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,515 · see citing works

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,348 · see citing works

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S. A., Stein, H., & Jaffe, E. S. (2011) · Blood · doi:10.1182/blood-2011-01-293050 · Cited by 2,007 · see citing works

Myelodysplastic Syndromes

Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., Castro, C. M. D., Deeg, H. J., Frankfurt, O., Gaensler, K. M. L., Garcia-Manero, G., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0104 · Cited by 1,623 · see citing works

Age and acute myeloid leukemia

Appelbaum, F. R., Gundacker, H. M., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,352 · see citing works

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991 · see citing works

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Bloomfield, C. D., Lawrence, D. D., Byrd, J. C., Carroll, A. J., Pettenati, M. J., Tantravahi, R. V., Patil, S., Davey, F. R., Berg, D. T., Schiffer, C. A., et al. (1998) · PubMed · Cited by 687 · see citing works

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608 · see citing works

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487 · see citing works

Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

Østgård, L. S. G., Medeiros, B. C., Sengeløv, H., Nørgaard, M., Andersen, M. K., Dufva, I. H., Friis, L. S., Kjeldsen, E., Marcher, C. W., Preiss, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0890 · Cited by 451 · see citing works

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

Mrózek, K., Marcucci, G., Nicolet, D., Maharry, K. S., Becker, H., Whitman, S. P., Metzeler, K. H., Schwind, S., Wu, Y.-Z., Kohlschmidt, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4738 · Cited by 406 · see citing works

Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity

Marie, J., Zittoun, R., & Sikic, B. (1991) · Blood · doi:10.1182/blood.v78.3.586.586 · Cited by 395 · see citing works

High-dose cytosine arabinoside therapy for refractory leukemia

Herzig, R. H., Wolff, S., Lazarus, H., Phillips, G. L., Karanes, C., & Herzig, G. P. (1983) · Blood · doi:10.1182/blood.v62.2.361.361 · Cited by 372 · see citing works

Myelodysplastic syndromes

Nimer, S. D. (2008) · Blood · doi:10.1182/blood-2007-08-078139 · Cited by 337 · see citing works

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B

Fröhling, S., Schlenk, R. F., Käyser, S., Morhardt, M., Benner, A., Döhner, K., Döhner, H., & for the German-Austrian AML Study Group (2006) · Blood · doi:10.1182/blood-2006-04-014324 · Cited by 300 · see citing works

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

Björkholm, M., Derolf, Å. R., Hultcrantz, M. L., Kristinsson, S. Y., Ekstrand, C., Goldin, L. R., Andréasson, B., Birgegård, G., Linder, O., Malm, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7542 · Cited by 244 · see citing works

Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines

Qin, T., Jelı́nek, J., Si, J., Shu, J., & Issa, J. J. (2008) · Blood · doi:10.1182/blood-2008-02-140038 · Cited by 238 · see citing works

Therapy-related leukemia and myelodysplasia: susceptibility and incidence

Leone, G., Pagano, L., Ben-Yehuda, D., & Voso, M. T. (2007) · Haematologica · doi:10.3324/haematol.11034 · Cited by 236 · see citing works

Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?

Barrett, J., Saunthararajah, Y., & Molldrem, J. (2000) · Seminars in Hematology · doi:10.1016/s0037-1963(00)90027-1 · Cited by 207 · see citing works

Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children

Kojima, S., Ohara, A., Tsuchida, M., Kudoh, T., Hanada, R., Okimoto, Y., Kaneko, T., Takano, T., Ikuta, K., & Tsukimoto, I. (2002) · Blood · doi:10.1182/blood.v100.3.786 · Cited by 191 · see citing works

Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.

Jabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2005) · Blood · doi:10.1182/blood.v106.11.1846.1846 · Cited by 183 · see citing works

Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system

Weinberg, O. K., Seetharam, M., Ren, L., Seo, K., Ma, L., Merker, J. D., Gotlib, J. R., Zehnder, J. L., & Arber, D. A. (2009) · Blood · doi:10.1182/blood-2008-10-182782 · Cited by 165 · see citing works

Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.

Kantharidis, P., El‐Osta, A., DeSilva, M., Wall, D. M., Hu, X. F., Slater, A. A., Nadalin, G., Parkin, J. D., & Zalcberg, J. R. (1997) · PubMed · Cited by 144 · see citing works

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G‐CSF (CLAG‐M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group

Wierzbowska, A., Robak, T., Pluta, A., Wawrzyniak, E., Cebula‐Obrzut, B., Hołowiecki, J., Kyrcz‐Krzemień, S., Grosicki, S., Giebel, S., Skotnicki, A. B., et al. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00988.x · Cited by 141 · see citing works

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML

Dicker, F., Haferlach, C., Sundermann, J., Wendland, N., Weiss, T., Kern, W., Haferlach, T., & Schnittger, S. (2010) · Leukemia · doi:10.1038/leu.2010.124 · Cited by 140 · see citing works

How Cancer Shapes Evolution and How Evolution Shapes Cancer

Casás‐Selves, M., & DeGregori, J. V. (2011) · Evolution Education and Outreach · doi:10.1007/s12052-011-0373-y · Cited by 134 · see citing works

FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience

Pastore, D., Specchia, G., Carluccio, P., Liso, A., Mestice, A., Rizzi, R., Greco, G., Buquicchio, C., & Liso, V. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0624-2 · Cited by 104 · see citing works

Etiology and Management of Therapy-Related Myeloid Leukemia

Larson, R. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.453 · Cited by 95 · see citing works

Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?

Larson, R. A. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2006.10.006 · Cited by 90 · see citing works

High-Dose Cytarabine (HD araC) in the Treatment of Leukemias: a Review

Reese, N., & Schiller, G. J. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0156-3 · Cited by 86 · see citing works

Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome

Bello, C. M., Yu, D., Komrokji, R. S., Zhu, W., Wetzstein, G. A., List, A. F., & Lancet, J. E. (2010) · Cancer · doi:10.1002/cncr.25598 · Cited by 82 · see citing works

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

Takahashi, K., Jabbour, E. J., Wang, X., Luthra, R., Bueso‐Ramos, C. E., Patel, K. P., Pierce, S. A., Yang, H., Wei, Y., Daver, N. G., et al. (2013) · Leukemia · doi:10.1038/leu.2013.165 · Cited by 64 · see citing works

Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics

Fernández‐Mercado, M., Yip, B. H., Pellagatti, A., Davies, C. H., Larráyoz, M. J., Kondo, T., Pérez, C., Killick, S. B., McDonald, E.-J., Odero, M. D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042334 · Cited by 61 · see citing works

Reasons for treating secondary AML as de novo AML

Østgård, L. S. G., Kjeldsen, E., Holm, M. S., Brown, P. D. N., Pedersen, B. B., Bendix, K., Johansen, P., Kristensen, J. S., & Nørgaard, J. M. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01464.x · Cited by 57 · see citing works

Therapy-Related Myeloid Neoplasms

Czader, M., & Orazi, A. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcpd85mcohhcomq · Cited by 57 · see citing works

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

Prébet, T., Gore, S. D., Thépot, S., Esterni, B., Quesnel, B., Beyne‐Rauzy, O., Dreyfus, F., Gardin, C., Fenaux, P., & Vey, N. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09076.x · Cited by 56 · see citing works

Myelodysplastic/Myeloproliferative Neoplasms

Foucar, K. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcpj71ptvikgevt · Cited by 49 · see citing works

An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling

Flach, J., Dicker, F., Schnittger, S., Schindela, S., Kohlmann, A., Haferlach, T., Kern, W., & Haferlach, C. (2011) · Leukemia · doi:10.1038/leu.2010.304 · Cited by 41 · see citing works

Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia

Jabbour, E. J., Garcia‐Manero, G., Cortes, J. E., Ravandi, F., Plunkett, W. K., Gandhi, V. V., Faderl, S. H., O'Brien, S. M., Borthakur, G. M., Kadia, T. M., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.03.003 · Cited by 35 · see citing works

Transformation of myelodysplastic syndromes into acute myeloid leukemias.

Shi, J., Shao, Z., Liu, H. S., Bai, J., Cao, Y., He, G., Tu, M., Wang, X., Hao, Y., Yang, T., et al. (2004) · PubMed · Cited by 33 · see citing works

Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML

Preiss, B., Bergmann, O. J., Friis, L. S., Sørensen, A. G., Frederiksen, M., Gadeberg, O., Mourits‐Andersen, T., Oestergaard, B., & Kerndrup, G. B. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2010.06.013 · Cited by 31 · see citing works

Blockade of invariant TCR-CD1d interaction specifically inhibits antibody production against blood group A carbohydrates

Tazawa, H., Irei, T., Tanaka, Y., Igarashi, Y., Tashiro, H., & Ohdan, H. (2013) · Blood · doi:10.1182/blood-2012-02-407452 · Cited by 30 · see citing works

Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database

Shukron, O., Vainstein, V., Kündgen, A., Germing, U., & Agur, Z. (2012) · American Journal of Hematology · doi:10.1002/ajh.23257 · Cited by 29 · see citing works

Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients

Isidori, A., Venditti, A., Maurillo, L., Buccisano, F., Loscocco, F., Manduzio, P., Sparaventi, G., Amadori, S., & Visani, G. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2013.858018 · Cited by 27 · see citing works

Secondary acute myeloid leukemia

Bennett, J. M. (1995) · Leukemia Research · doi:10.1016/0145-2126(95)00049-t · Cited by 20 · see citing works

High-dose cytosine arabinoside therapy for refractory leukemia

Herzig, R., Wolff, S. N., Lazarus, H. M., et al. (1983) · Blood · doi:10.1182/blood.v62.2.361.bloodjournal622361 · Cited by 15 · see citing works

Acute Myeloid Leukemia Following a Myeloproliferative Neoplasm: Clinical Characteristics, Genetic Features and Effects of Therapy

Heaney, M. L., & Soriano, G. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0154-5 · Cited by 14 · see citing works

Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure

Shin, S.-H., Yahng, S.-A., Yoon, J.-H., Lee, S. U., Cho, B.-S., Eom, K.-S., Lee, S., Min, C.-K., Kim, H.-J., Cho, S.-G., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.214 · Cited by 14 · see citing works

Molecular, Cytogenetic and Genetic Abnormalities in MDS and Secondary AML

Padua, R. A., McGlynn, A., & McGlynn, H. (2001) · Cancer treatment and research · doi:10.1007/978-1-4615-1463-3_8 · Cited by 13 · see citing works

Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?

DeAngelo, D. J., Stein, E. M., & Ravandi, F. (2016) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbk_161258 · Cited by 12 · see citing works

[Clinical analysis of 24 cases of acute myeloid leukemia with 3q abnormalities].

Lu, Y., Chen, Z., Xu, W., Mu, Q., & Jin, J. (2010) · PubMed · doi:10.3785/j.issn.1008-9292.2010.03.005 · Cited by 2 · see citing works

Assessment Of Human Equilibrative Nucleoside Transporter 1 (hENT1) – Expression By Flow Cytometry In Acute Myeloid Leukemia and Myelodysplastic Syndromes and Correlation To Clinical Outcome In Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy

Bellos, F., Davis, B. H., Culp, N. B., Booij, B. B., Schnittger, S., Haferlach, C., Haferlach, T., & Kern, W. (2013) · Blood · doi:10.1182/blood.v122.21.2582.2582 · Cited by 2 · see citing works

High-dose cytosine arabinoside therapy for refractory leukemia.

Fey, M. (1984) · PubMed · Cited by 1 · see citing works

High-dose cytosine arabinoside therapy for refractory leukemia [letter]

Fey, M. F. (1984) · Blood · doi:10.1182/blood.v64.3.758a.758a · Cited by 1 · see citing works

High-dose cytosine arabinoside therapy for refractory leukemia [letter]

Fey, M. (1984) · Blood · doi:10.1182/blood.v64.3.758a.bloodjournal643758a · Cited by 1 · see citing works

Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges

Shallis, R. M., Wang, R., Davidoff, A. J., Ma, X., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.005 · Cited by 949 · see citing works

Osteosarcoma

Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660 · see citing works

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Dinardo, C. D., Maiti, A., Rausch, C. R., Pemmaraju, N., Naqvi, K., Daver, N. G., Kadia, T. M., Borthakur, G. M., Ohanian, M. N., Alvarado, Y., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30210-6 · Cited by 324 · see citing works

How I treat acute myeloid leukemia in the era of new drugs

Dinardo, C. D., & Wei, A. H. (2019) · Blood · doi:10.1182/blood.2019001239 · Cited by 293 · see citing works

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Short, N. J., Bravo, G. M., Hwang, H., Ning, J., Franquiz, M. J., Kanagal‐Shamanna, R., Patel, K. P., Dinardo, C. D., Ravandi, F., Garcia‐Manero, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003120 · Cited by 181 · see citing works

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models

Minzel, W., Venkatachalam, A., Fink, A., Hung, E., Brachya, G., Burstain, I., Shaham, M., Rivlin, A., Omer, I., Zinger, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.045 · Cited by 155 · see citing works

<i>TP53</i> copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Tashakori, M., Kadia, T., Loghavi, S., Daver, N., Kanagal-Shamanna, R., Pierce, S., Sui, D., Wei, P., Khodakarami, F., Tang, Z., et al. (2022) · Blood · doi:10.1182/blood.2021013983 · Cited by 111 · see citing works

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Venugopal, S., Takahashi, K., Daver, N. G., Maiti, A., Borthakur, G. M., Loghavi, S., Short, N. J., Ohanian, M. N., Masárová, L., Issa, G. C., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-021-00604-2 · Cited by 96 · see citing works

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

Kadia, T. M., Cortes, J. E., Ravandi, F., Jabbour, E. J., Konopleva, M. Y., Benton, C. B., Burger, J. A., Sasaki, K., Borthakur, G. M., Dinardo, C. D., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30132-7 · Cited by 96 · see citing works

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

Bravo, G. M., Kanagal‐Shamanna, R., Class, C. A., Sasaki, K., Ravandi, F., Cortes, J. E., Daver, N. G., Takahashi, K., Short, N. J., Dinardo, C. D., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25769 · Cited by 68 · see citing works

Trisomy 8 in acute myeloid leukemia

Hemsing, A. L., Hovland, R., Tsykunova, G., & Reikvam, H. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1657400 · Cited by 54 · see citing works

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Short, N. J., Müftüoğlu, M., Ong, F., Nasr, L. F., Macaron, W., Bravo, G. M., Alvarado, Y., Basyal, M., Daver, N. G., Dinardo, C. D., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01476-8 · Cited by 53 · see citing works

ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia

Ebner, J., Schmoellerl, J., Piontek, M., Manhart, G., Troester, S., Carter, B. Z., Neubauer, H. A., Moriggl, R., Szakács, G., Zuber, J. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41229-2 · Cited by 50 · see citing works

More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate

Klepin, H. D., Estey, E. H., & Kadia, T. M. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239097 · Cited by 51 · see citing works

Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia

Higgins, A. S., & Shah, M. V. (2020) · Genes · doi:10.3390/genes11070749 · Cited by 50 · see citing works

The leukemia strikes back: a review of pathogenesis and treatment of secondary AML

Cheung, E., Perissinotti, A. J., Bixby, D. L., Burke, P. W., Pettit, K. M., Benitez, L. L., Brown, J. M., Scappaticci, G. B., & Marini, B. L. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03606-0 · Cited by 48 · see citing works

Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML

Tsai, C., Tang, J., Tien, F., Kuo, Y., Wu, D.-C., Lin, C., Tseng, M., Peng, Y., Hou, M.-F., Chuang, Y., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003738 · Cited by 49 · see citing works

Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment

de Leeuw, D. C., Ossenkoppele, G. J., & Janssen, J. J. W. M. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01299-9 · Cited by 47 · see citing works

The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy

Mendez, L., Posey, R. R., & Pandolfi, P. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01162 · Cited by 46 · see citing works

Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study

Sengsayadeth, S. M., Gatwood, K. S., Boumendil, A., Labopin, M., Finke, J., Ganser, A., Stelljes, M., Ehninger, G., Beelen, D. W., Niederwieser, D. W., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018019976 · Cited by 43 · see citing works

Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors

Boscaro, E., Urbino, I., Catania, F. M., Arrigo, G., Secreto, C., Olivi, M., D’Ardìa, S., Frairia, C., Giai, V., Freilone, R., et al. (2023) · Cancers · doi:10.3390/cancers15133512 · Cited by 40 · see citing works

Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry

Shouval, R., Fein, J. A., Labopin, M., Cho, C., Bazarbachi, A. A., Baron, F., Bug, G., Ciceri, F., Corbacioglu, S., Galimard, J., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30394-x · Cited by 33 · see citing works

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes

Rivera, D., Kim, K., Kanagal‐Shamanna, R., Borthakur, G. M., Bravo, G. M., Daver, N. G., Dinardo, C. D., Short, N. J., Yilmaz, M. E., Pemmaraju, N., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26731 · Cited by 32 · see citing works

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Short, N. J., Venugopal, S., Qiao, W., Kadia, T. M., Ravandi, F., Macaron, W., Dinardo, C. D., Daver, N. G., Konopleva, M. Y., Borthakur, G. M., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01229-z · Cited by 31 · see citing works

Secondary Acute Myeloid Leukemia

Winer, E. S. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.003 · Cited by 29 · see citing works

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM

Huemer, F., Melchardt, T., Jansko, B., Wahida, A., Jilg, S., Jost, P. J., Klieser, E., Steiger, K., Magnes, T., Pleyer, L., et al. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13218 · Cited by 27 · see citing works

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

Reville, P. K., Sasaki, K., Kantarjian, H. M., Daver, N. G., Yilmaz, M. E., Dinardo, C. D., Short, N. J., Borthakur, G. M., Pemmaraju, N., Mehta, R. S., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26451 · Cited by 26 · see citing works

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

Short, N. J., Borthakur, G. M., Pemmaraju, N., Dinardo, C. D., Kadia, T. M., Jabbour, E. J., Konopleva, M. Y., Macaron, W., Ning, J., Ma, J., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2062345 · Cited by 26 · see citing works

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia

Maiti, A., & Konopleva, M. Y. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000567 · Cited by 25 · see citing works

Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst

Shallis, R. M., Weiss, J. J., Deziel, N. C., & Gore, S. D. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100760 · Cited by 24 · see citing works

Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

Kadia, T. M., Ravandi, F., Borthakur, G. M., Konopleva, M. Y., Dinardo, C. D., Daver, N. G., Pemmaraju, N., Kanagal‐Shamanna, R., Wang, X., Huang, X., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26206 · Cited by 24 · see citing works

Clinical Impact of Transformation to Acute Myeloid Leukemia in Patients With Higher-Risk Myelodysplastic Syndromes

Kota, V. K., Ogbonnaya, A., Farrelly, E., Schroader, B. K., Raju, A., Kristo, F., & Dalal, M. R. (2022) · Future Oncology · doi:10.2217/fon-2022-0334 · Cited by 24 · see citing works

The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia

Vulaj, V., Perissinotti, A. J., Uebel, J. R., Nachar, V. R., Scappaticci, G. B., Crouch, A., Bixby, D. L., Burke, P. W., Maillard, I. P., Talpaz, M., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.05.011 · Cited by 24 · see citing works

How to address second and therapy‐related acute myelogenous leukaemia

Oliai, C. H., & Schiller, G. J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16354 · Cited by 23 · see citing works

A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia

Sweet, K. L., Bhatnagar, B., Döhner, H., Donnellan, W., Frankfurt, O., Heuser, M., Kota, V. K., Liu, H., Raffoux, E., Roboz, G. J., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1950706 · Cited by 22 · see citing works

Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape

Short, N. J., Tallman, M. S., Pollyea, D. A., Ravandi, F., & Kantarjian, H. M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00067 · Cited by 22 · see citing works

Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options

Richardson, D. R., Green, S. D., Foster, M. C., & Zeidner, J. F. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00608-6 · Cited by 21 · see citing works

Treatment of Acute Myeloid Leukemia in Older Adults

Alsouqi, A., Geramita, E. M., & Im, A. (2023) · Cancers · doi:10.3390/cancers15225409 · Cited by 23 · see citing works

Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia

Short, N. J., & Kantarjian, H. M. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00167-3 · Cited by 20 · see citing works

Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia

Kamath, G. R., Tremblay, D. A., Coltoff, A. R., Caro, J., Lancman, G., Bhalla, S., Najfeld, V., Mascarenhas, J. O., & Taioli, E. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz014 · Cited by 20 · see citing works

The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia

Shallis, R. M., Boddu, P. C., Bewersdorf, J. P., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100639 · Cited by 19 · see citing works

Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia

Limongello, R., Marra, A., Mancusi, A., Bonato, S., Hoxha, E., Ruggeri, L., Hui, S. K., Velardi, A., & Pierini, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.695051 · Cited by 18 · see citing works

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation

Senapati, J., Kantarjian, H. M., Haddad, F., Short, N. J., Borthakur, G. M., Kanagal‐Shamanna, R., Tang, G., Jabbour, E. J., Dinardo, C. D., Daver, N. G., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27561 · Cited by 17 · see citing works

Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk

Kim, S., Yoon, S., Hong, J., Shin, D., Koh, Y., Byun, J. M., & Kim, I. (2020) · Anticancer Research · doi:10.21873/anticanres.14269 · Cited by 17 · see citing works

Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML

Lalayanni, C., Gavriilaki, E., Athanasiadou, A., Iskas, M., Papathanasiou, M., Marvaki, A., Dimou-Mpesikli, S., Papaioannou, G., Mallouri, D., Batsis, I., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.09.019 · Cited by 17 · see citing works

Treatment intensification with FLAG‐Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long‐term follow up of the MRC AML15 trial

Russell, N. H., Hills, R. K., Kjeldsen, L., Dennis, M., & Burnett, A. K. (2021) · British Journal of Haematology · doi:10.1111/bjh.17974 · Cited by 16 · see citing works

Phase II study of cladribine, idarubicin, and ara‐C ( CLIA ) with or without sorafenib as initial therapy for patients with acute myeloid leukemia

Kadia, T. M., Ravandi, F., Molica, M., Bataller, Á., Borthakur, G. M., Daver, N. G., Jabbour, E. J., Dinardo, C. D., Pemmaraju, N., Jain, N., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27054 · Cited by 16 · see citing works

How I treat secondary acute myeloid leukemia

Green, S. D., & Wang, E. S. (2024) · Blood · doi:10.1182/blood.2024024011 · Cited by 16 · see citing works

Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia

Raneros, A. B., Rodríguez, R. M. A., Flórez, A. B., Palomo, P., Colado, E., Minguela, A., Suárez-Álvarez, B., & López‐Larrea, C. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1897294 · Cited by 16 · see citing works

CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia

Lee, D. C., Jain, A. G., Deutsch, Y. E., Eatrides, J. M., Chan, O., Padron, E., Kuykendall, A. T., Komrokji, R. S., Lancet, J. E., Sallman, D. A., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.06.001 · Cited by 16 · see citing works

Upregulated mitosis-associated genes CENPE, CENPF, and DLGAP5 predict poor prognosis and chemotherapy resistance of Acute Myeloid Leukemia

Shi, M., Guo, H., Bai, Y., Niu, J., Niu, X., Sun, K., & Chen, Y. (2022) · Cancer Biomarkers · doi:10.3233/cbm-203170 · Cited by 15 · see citing works

Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia

Ambinder, A. J., & Dezern, A. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1033534 · Cited by 16 · see citing works

A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice

Rajagopalan, A., Feng, Y., Gayatri, M. B., Ranheim, E., Klungness, T., Matson, D., Lee, M.-H., Jung, M., Zhou, Y., Gao, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci173116 · Cited by 16 · see citing works

Treatment Strategies for Therapy-related Acute Myeloid Leukemia

Dhakal, P., Pyakuryal, B., Pudasainee, P., Rajasurya, V., Gundabolu, K., & Bhatt, V. R. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.12.007 · Cited by 15 · see citing works

Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China

Dou, X., Dan, C., Zhang, D., Zhou, H., He, R., Zhou, G., Zhu, Y., Fu, N., Niu, B., Xu, S., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35125 · Cited by 14 · see citing works

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML

Molica, M., Perrone, S., Mazzone, C., Cesini, L., Canichella, M., & de Fabritiis, P. (2022) · Cancers · doi:10.3390/cancers14122843 · Cited by 14 · see citing works

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis

Middeke, J. M., Teipel, R., Röllig, C., Stasik, S., Zebisch, A., Sill, H., Krämer, M., Scholl, S., Hochhaus, A., Jost, E., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1864354 · Cited by 13 · see citing works

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy

Jen, W., Sasaki, K., Ravandi, F., Kadia, T. M., Wang, S. A., Wang, W., Loghavi, S., Daver, N. G., Dinardo, C. D., Issa, G. C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013826 · Cited by 12 · see citing works

Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials

Ramadan, S. M., Suciu, S., Stevens‐Kroef, M., Willemze, R., Amadori, S., de Witte, T., Löwenberg, B., Muus, P., Labar, B., Meert, L., et al. (2020) · Cancers · doi:10.3390/cancers12113334 · Cited by 12 · see citing works

AHR signaling pathway reshapes the metabolism of AML/MDS cells and potentially leads to cytarabine resistance

Jia, Y., Guo, J., Zhao, Y., Zhang, Z., Shi, L., Fang, Y., Wu, D., Wu, L., & Chang, C. (2021) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmab017 · Cited by 11 · see citing works

Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients

Hecker-Nolting, S., Langer, T., Blattmann, C., Kager, L., & Bielack, S. S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s287908 · Cited by 10 · see citing works

Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype

Galera, P. K., Dilip, D., Derkach, A., Chan, A. C. L., Zhang, Y., Persaud, S., Mishra, T., Kramer, K., Kathpalia, M., Liu, Y., et al. (2025) · Blood · doi:10.1182/blood.2024026273 · Cited by 11 · see citing works

Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?

Uy, G. L., DeAngelo, D. J., Lozier, J. N., Fisher, D. M., Jonas, B. A., Magnani, J. L., Becker, P. S., Lazarus, H. M., & Winkler, I. G. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101184 · Cited by 10 · see citing works

The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia

Cooperrider, J. H., Shukla, N., Nawas, M. T., & Patel, A. A. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00342 · Cited by 10 · see citing works

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

Orvain, C., Arboli, E. R., Othus, M. K. D., Sandmaier, B. M., Deeg, H. J., Appelbaum, F. R., & Walter, R. B. (2023) · Cancers · doi:10.3390/cancers15020352 · Cited by 9 · see citing works

Identification of a prognostic model based on costimulatory molecule-related subtypes and characterization of tumor microenvironment infiltration in acute myeloid leukemia

Mao, Y., Hu, Z., Xu, X., Xu, J., Wu, C., Jiang, F., & Zhou, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.973319 · Cited by 9 · see citing works

Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper

Dennis, M., Copland, M., Kaur, H., Kell, J., Nikolousis, E., Mehta, P., Palanicawandar, R., Potter, V. T., Raj, K. K., Thomas, I., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18369 · Cited by 8 · see citing works

Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials

Jammal, N., Rausch, C. R., Kadia, T. M., & Pemmaraju, N. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1847272 · Cited by 8 · see citing works

Network Pharmacology and Experimental Validation Reveal the Effects of Chidamide Combined With Aspirin on Acute Myeloid Leukemia-Myelodysplastic Syndrome Cells Through PI3K/AKT Pathway

Liang, S., Zhou, X., Cai, D., Rodrigues‐Lima, F., Chi, J., & Wang, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.685954 · Cited by 8 · see citing works

Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia

Parmar, K., Kundu, R., Maiti, A., & Ball, S. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107546 · Cited by 7 · see citing works

Prognostic Significance of Fms-Like Tyrosine Kinase 3 Internal Tandem Duplication Mutation in Non-Transplant Adult Patients with Acute Myeloblastic Leukemia: A Systematic Review and Meta-Analysis

Rinaldi, I., Louisa, M., Wiguna, F., Budiani, E., Mahardhika, J. C., & Hukmi, K. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.10.2827 · Cited by 6 · see citing works

Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt

Sedeta, E. T., Jemal, A., Nisotel, L. E., & Sung, H. (2024) · Cancer · doi:10.1002/cncr.35214 · Cited by 6 · see citing works

Evolution of Therapy for Older Patients With Acute Myeloid Leukemia

Kadia, T. M., & Wei, A. H. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000574 · Cited by 6 · see citing works

Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia

Reville, P. K., & Kadia, T. M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0710-x · Cited by 6 · see citing works

Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial

Zhou, X., Mei, C., Zhang, J., Lu, Y., Lan, J., Lin, S., Zhang, Y., Kuang, Y., Ren, Y., Ma, L., et al. (2020) · Hematological Oncology · doi:10.1002/hon.2755 · Cited by 6 · see citing works

Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP / EBMT

Nagler, A., Kayser, S., Ferhat, A. T., Kröger, N. M., Eder, M., Socié, G., Blaise, D., Schroeder, T., Labussière‐Wallet, H., Maertens, J. A., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70164 · Cited by 5 · see citing works

Acute Myeloid Leukemia in Young Adults: Does Everyone Need a Transplant?

Roberts, M. D., Langston, A. A., & Heffner, L. T. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00574 · Cited by 5 · see citing works

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities

Boertjes, E. L., Grob, T., Hinai, A. S. A. A., Beverloo, B. H. B., Versluis, J., Kavelaars, F. G., Rijken, M., Compagne, K. G., Erpelinck-Verschueren, C. A. J., Sanders, M. A., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018408 · Cited by 4 · see citing works

Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study

Madrid, P. L., Boluda, B., Martínez‐López, J., Bergua, J., Arboli, E. R., Labrador, J., Sossa, C., Gil, C., Algarra, L., Lavilla, E., et al. (2025) · Cancer · doi:10.1002/cncr.35696 · Cited by 4 · see citing works

Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms

Jahn, J., Diamond, B. T., Hsu, J., Montoya, S., Totiger, T. M., Landgren, O., Maura, F., & Taylor, J. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107020 · Cited by 3 · see citing works

T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

Kayser, S., Nagler, A., Ferhat, A.-T. L. S., Sanz, J., Blaise, D., Koç, Y., Raiola, A. M., Busca, A., Kulagin, A., Vydra, J., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02951-9 · Cited by 3 · see citing works

A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience

Karasek, M., Armatys, A., Skarupski, M., Bołkuń, Ł., Budziszewska, B. K., Drozd-Sokolowska, J. E., Zarzycka, E., Mensah‐Glanowska, P., Gajewska, M., Hałka, J., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1395992 · Cited by 3 · see citing works

Behandling av akutt myelogen leukemi hos eldre

Reikvam, H., Dalgaard, J., Johansen, S., Tvedt, T. H. A., & Bruserud, Ø. (2019) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.18.0775 · Cited by 3 · see citing works

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review

Cortes, J. E., Candoni, A., Clark, R. E., Leber, B. F., Montesinos, P., Vyas, P., Zeidan, A. M., & Heuser, M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1817445 · Cited by 3 · see citing works

Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia

Asghari, H. H., & Lancet, J. E. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1719093 · Cited by 3 · see citing works

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities

Hassanein, M. F. R., Fakih, R. O. E., Rasheed, W. K., Ahmed, S. O., Shaheen, M., Chaudhri, N. A., Alsharif, F. Z., Ahmed, S., Hanbali, A. S., Alshaibani, A., et al. (2021) · eJHaem · doi:10.1002/jha2.136 · Cited by 3 · see citing works

Acute myeloid leukemia with mixed phenotype is characterized by RUNX1 mutations, stemness features and limited lineage plasticityPreprint

Galera, P. K., Dilip, D., Derkach, A., Chan, A. C. L., Zhang, Y., Persuad, S., Mishera, T., Liu, Y., Famulare, C. A., Gao, Q., et al. (2023) · medRxiv · doi:10.1101/2023.11.01.23297696 · Cited by 3 · see citing works

A Phase 2 study of CPX‐351 in combination with venetoclax in patients with newly diagnosed high‐risk acute myeloid leukemia

Jen, W., Croden, J., Almanza, E., Dinardo, C. D., Chien, K. S., Hammond, D. E., Qiao, W., Alvarado, Y., Masárová, L., Quesada, A. E., et al. (2025) · HemaSphere · doi:10.1002/hem3.70214 · Cited by 2 · see citing works

Consenso de leucemia mieloide aguda en México

Arana-Luna, L. L., Alvarado‐Ibarra, M., Silva-Michel, L. G., Morales-Maravilla, A., González-Rubio, M. D. C., Chavez-Aguilar, L. A., Tena-Iturralde, M. F., Mojica-Balderas, L., Zapata-Canto, N. P., Galindo-Delgado, P., et al. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m21000597 · Cited by 2 · see citing works

AHR signaling pathway mediates mitochondrial oxidative phosphorylation which leads to cytarabine resistance

Jia, Y., Li, X., Chen, L., Li, L., Zhang, S., Huang, W., & Zhang, H. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024022 · Cited by 2 · see citing works

Characteristics and Survival of Secondary Acute Myeloid Leukemia From Myelodysplastic Syndromes in Older Adults: A Population Analysis

Batra, A., Sparks, A. D., Singh, R., Zakai, N. A., & Herrera, D. A. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.012 · Cited by 2 · see citing works

Molecular insights and treatment innovations: Advancing outcomes in acute myeloid leukemia with myelodysplasia‑related changes (Review)

Qiu, H., Zhang, C., Ma, X., & Li, Y. (2025) · Oncology Reports · doi:10.3892/or.2025.8887 · Cited by 2 · see citing works

Efficacy of Azacitidine Plus Venetoclax in Acute Myeloid Leukemia Transformed from Myelodysplastic Syndrome after Failure of Azacitidine Monotherapy

Furumoto, T., Ando, K., Toriyama, E., Hata, T., Katsuoka, S., Nishimura, S., Ichinose, M., Hashimoto, M., Fujioka, M., Sakaki, C., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5312-25 · Cited by 2 · see citing works

Pediatric Germline Predisposition to Myeloid Neoplasms

Thompson, C., Ariagno, S. N., & Kohorst, M. A. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00681-5 · Cited by 2 · see citing works

Consensus in acute myeloid leukemia in Mexico

Arana-Luna, L. L., Alvarado‐Ibarra, M., Silva-Michel, L. G., Morales-Maravilla, A., González-Rubio, M. D. C., Chávez-Aguilar, L. A., Tena-Iturralde, M. F., Mojica-Balceras, L., Zapata-Canto, N., Galindo-Delgado, P., et al. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m21000598 · Cited by 2 · see citing works

Allogeneic stem cell transplantation remains an effective therapeutic approach for patients with therapy-related acute myeloid leukemia

Spałek, A. M., Woźniczka, K., Armatys, A., Matlak, K., Koclęga, A., Kata, D., Wieczorkiewicz-Kabut, A., & Helbig, G. (2021) · Acta Haematologica Polonica · doi:10.5603/ahp.2021.0016 · Cited by 2 · see citing works

Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351

Makishima, H., Mikasa, T., Isogaya, K., Miyamoto, T., Yamauchi, T., Yokota, A., Onozawa, M., Ando, K., Ogawa, Y., Usuki, K., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-03956-8 · Cited by 1 · see citing works

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Swaminathan, M., Dinardo, C. D., Maiti, A., Pemmaraju, N., Ohanian, M. N., Daver, N. G., Garcia‐Manero, G., Issa, G. C., Borthakur, G. M., Ravandi, F., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01265-1 · Cited by 1 · see citing works

Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation

Kashima, E., Sugimoto, Y., Nagaharu, K., Ohya, E., Ikejiri, M., Watanabe, Y., Kageyama, S., Oka, K., & Tawara, I. (2024) · Hematology · doi:10.1080/16078454.2024.2392908 · Cited by 1 · see citing works

Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients

Kamath, G. R., Tremblay, D. A., Coltoff, A. R., Caro, J., Lancman, G., Bhalla, S., Najfeld, V., Mascarenhas, J. O., & Taioli, E. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.12.006 · Cited by 1 · see citing works

Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes

Matsukawa, T., Yoshida, S. Y., Onozawa, M., Fujii, F., Nagai, J., Takahashi, T., Ota, S., Hashiguchi, J., Mori, A., Miyagishima, T., et al. (2026) · Figshare · doi:10.6084/m9.figshare.31310112

Differential Induction Among Younger Patients Diagnosed with Secondary Acute Myelogenous Leukemia Is Feasible By Cytogenetic/Molecular Risk Stratification

Afrough, A., Talukder, R., Yellapragada, S. V., Teegavarapu, P. S., Mims, M. P., & Rivero, G. (2019) · Blood · doi:10.1182/blood-2019-129183

Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML

Lalayanni, C., Gavriilaki, E., Athanasiadou, A., Iskas, M., Papathanasiou, M., Marvaki, A., Dimou-Mpesikli, S., Papaioannou, G., Mallouri, D., Batsis, I., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.09.019 · Cited by 17 · see citing works

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation

Senapati, J., Kantarjian, H. M., Haddad, F., Short, N. J., Borthakur, G. M., Kanagal‐Shamanna, R., Tang, G., Jabbour, E. J., Dinardo, C. D., Daver, N. G., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27561 · Cited by 17 · see citing works

Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk

Kim, S., Yoon, S., Hong, J., Shin, D., Koh, Y., Byun, J. M., & Kim, I. (2020) · Anticancer Research · doi:10.21873/anticanres.14269 · Cited by 17 · see citing works